BARD1 germline pathogenic in EOC: rare; included in HRR panels; PARPi benefit extrapolate...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-BARD1-GERMLINE-OVARIAN |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-OVARIAN |
| Sources | SRC-CIVIC SRC-ESMO-OVARIAN-2024 SRC-NCCN-OVARIAN-2025 |
Actionability Facts
| Biomarker | BIO-HRR-PANEL |
|---|---|
| Variant | BARD1 germline pathogenic |
| Disease | DIS-OVARIAN |
| ESCAT tier | IIB |
| Recommended combinations | niraparib maintenance, olaparib + bevacizumab (HRD-positive) |
| Evidence summary | BARD1 germline pathogenic in EOC: rare; included in HRR panels; PARPi benefit extrapolated from HRD-positive trial subgroups (PAOLA-1, NOVA non-gBRCA). ESCAT IIB / OncoKB Level 3B. |
Notes
Cascade testing per NCCN.
Used By
No reverse references found in the YAML corpus.